Introduction: Non-valvular atrial fibrillation (NVAF) is known as a robust risk factor for stroke. Recent reports have suggested a risk of dementia with NVAF, but much remains unknown regarding the relationship between this mechanism and the potential protective effects of novel anticoagulants (direct oral anticoagulants (DOACs), or non-vitamin K oral anticoagulants).
Methods and analysis: This study, the STRAtegy to obtain Warfarin or direct oral anticoagulant’s Benefit by Evaluating RegistRY (Strawberry study), is an investigator-initiated, multicenter, prospective, observational, longitudinal cohort study comparing the effects of warfarin therapy and DOACs on cerebrovascular diseases and cognitive impairment over an estimated duration of 36 months. Once a year for 3 years, the activities of daily living and cognitive functioning of non-demented patients with NVAF will be assessed. Demographics, risk factors, laboratory investigations, lifestyle, social background, and brain MRI will be assessed.
Ethics and dissemination: This protocol has been approved by the ethics committee of the National Center for Geriatrics and Gerontology (No. 1036) and complies with the Declaration of Helsinki. Informed consent will be obtained before study enrollment and only coded data will be stored in a secured database. The results will be published in peer-reviewed journals and presented at scientific meetings to ensure the applicability of the findings in clinical practice.
Study registration number: UMIN000025721

PROTECTIVE EFFECTS OF ORAL ANTICOAGULANTS ON CEREBROVASCULAR DISEASES AND COGNITIVE IMPAIRMENT IN PATIENTS WITH ATRIAL FIBRILLATION: PROTOCOL FOR A MULTICENTER, PROSPECTIVE, OBSERVATIONAL, LONGITUDINAL STUDY